Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dermatologic Management of Melanoma Involves Observation of Skin AEs and New Primary Melanomas

July 14th 2017

Jennifer A. Stein, MD, PhD, discusses the skin-related adverse events for patients on treatment for melanoma, as well as the importance of identifying new primary melanomas.

Encouraging Activity Seen With Glembatumumab Vedotin in Advanced Melanoma

July 14th 2017

The antibody-drug conjugate glembatumumab vedotin demonstrated an 11% overall response rate in patients with refractory advanced melanoma who had received prior treatment with a checkpoint inhibitor and duration of response.

Long-Term and Brain Mets Data Demonstrate Strong Dabrafenib/Trametinib Efficacy in Melanoma

July 9th 2017

Jeffrey S. Weber, MD, PhD, discusses both pivotal studies for dabrafenib/trametinib in patients with melanoma and any unanswered questions that remain after the extensive 5-year follow-up.

Positive Results from First Randomized Study Assessing T-VEC/Ipilimumab Combo in Advanced Melanoma

July 7th 2017

The addition of T-VEC (T-VEC; Imlygic), a herpes simplex virus 1-based oncolytic virus, to CTLA-4 inhibitor ipilimumab (Yervoy) improves the objective response rate in patients with unresected stage IIIb to IV melanoma.

Dr. Schilling on the Importance of Distinguishing Ocular Melanoma

July 6th 2017

Bastian Schilling, MD, University of Wuerzburg, discusses different types of ocular melanoma and the importance of distinguishing this subtype.

Dr. Daud on the Combinations of Immunotherapy for Melanoma

July 6th 2017

Adil Daud, MD, a clinical professor, Department of Medicine at University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses potential combinations of immunotherapy for the treatment of patients with melanoma.

Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma

July 6th 2017

Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.

Adjuvant Nivolumab Improves RFS Versus Ipilimumab in Melanoma

July 5th 2017

Adjuvant nivolumab (Opdivo) extended recurrence-free survival compared with adjuvant ipilimumab (Yervoy) in patients with advanced melanoma enrolled in the phase III CheckMate-238 trial.

Expert Discusses IDO/PD-1 and Other Emerging Combos in Melanoma

June 30th 2017

Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.

Dr. Kondziolka on Therapy for Patients With Melanoma Who Have Brain Mets

June 30th 2017

Doug Kondziolka, MD, professor and vice chair of Clinical Research, NYU Langone Medical Center, discusses therapeutic approaches for patients with melanoma who have brain metastases.

Dr. Weber on Next Steps With Pembrolizumab as Melanoma Treatment

June 30th 2017

Jeffrey S. Weber, MD, PhD, a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the next steps with the PD-1 inhibitor pembrolizumab (Keytruda) as treatment for patients with melanoma.

Dabrafenib Shows Remarkable Intracranial Activity in Patients With BRAF-Mutant Melanoma and Brain Metastases

June 30th 2017

Monotherapy with potent BRAF inhibitor dabrafenib (Tafinlar) resulted in a disease control rate of 83% in patients with BRAF-mutant melanoma and brain metastases.

Clinical Trials Are Essential in the Adjuvant Setting for High-Risk Melanoma

June 30th 2017

Anna C. Pavlick, DO, discusses adjuvant therapy for patients with high-risk melanoma.

Dr. Andtbacka on the OPTiM Results of T-VEC for Melanoma

June 30th 2017

Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.

Dr. Ross on the Treatment of Liver Metastasis in Melanoma

June 30th 2017

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses treatment for liver metastasis in patients with melanoma.

Weighing Efficacy and Tolerability for Adjuvant Ipilimumab in Advanced Melanoma

June 30th 2017

Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.

Adjuvant PD-1 Inhibition on Horizon in Melanoma

June 30th 2017

Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.

Weber Says Pembrolizumab/Epacadostat Could Become Frontline Treatment of Choice in Melanoma

June 30th 2017

Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).

Expert Highlights Impressive Long-Term Activity With BRAF/MEK Combos in Melanoma

June 30th 2017

Melissa A. Wilson, MD, PhD, discussed the promising results with BRAF/MEK inhibitor combinations in melanoma and what ongoing studies have the potential to alter the landscape again.

Expert Discusses Adjuvant Ipilimumab Regimens in Melanoma

June 29th 2017

Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.